Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia

Fig. 3

Progression-free survival and overall survival. A, B Kaplan–Meier estimates of Progression-free survival of 19 responded patients (A) and overall survival of all 20 treated patients (B). C, D Kaplan–Meier estimates of progression-free survival of 19 responded patients (C), and overall survival of all 20 treated patients (D), according to whether or not a subsequent SCT consolidation is conducted. CAR—chimeric antigen receptor; NE—not estimable; SCT—stem cell transplantation; PFS—progression-free survival; OS—overall survival; CI— confidence interval

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us